The global Antisense and RNAi Therapeutics Market was valued at USD 4.15 billion in 2023, projected to reach USD 18.48 billion by 2032 with a CAGR of 18.05%. Demand is driven by a 10% increase in rare genetic diseases affecting 30 million Americans, a 7% rise in US federal research funding, and FDA approvals for cutting-edge therapies. RNAi technology leads with a 60% market share, while antisense RNA holds 40%, both showing promising growth potential. North America leads the market at 42%, with Europe and Asia-Pacific expected to see strong growth. Recent developments include positive Phase 3 results for antisense drugs targeting ALS, FDA approval for an RNAi therapy, and portfolio expansions in oncology and rare neurological diseases. The Antisense and RNAi therapeutics market is projected to reach USD 18.48 billion by 2032, with a CAGR of 18.05% from 2024 to 2032. Key segments include technology (RNA Interference, Antisense RNA), applications (Genetic Disease, Cancer, Infectious Disease), and regional analysis covering North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.

For more detailed information on the Antisense and RNAi therapeutics market analysis and outlook, visit https://www.snsinsider.com/reports/antisense-and-rnai-therapeutics-market-4493. SNS Insider is a leading market research and consulting agency, providing clients with accurate market data, consumer insights, and opinions to make informed decisions in a rapidly changing environment. Contact [email protected] for customization options.

Read more at GlobeNewswire: Antisense and RNAi Therapeutics Market to Reach USD 18.48